A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models
To determine whether multivariate machine learning models of algorithmically assessed magnetic resonance imaging (MRI) features from breast cancer patients are associated with Oncotype DX (ODX) test recurrence scores.
A set of 261 female patients with invasive breast cancer, pre-operative dynamic contrast enhanced magnetic resonance (DCE-MR) images and available ODX score at our institution was identified. A computer algorithm extracted a comprehensive set of 529 features from the DCE-MR images of these patients. The set of patients was divided into a training set and a test set. Using the training set we developed two machine learning-based models to discriminate (1) high ODX scores from intermediate and low ODX scores, and (2) high and intermediate ODX scores from low ODX scores. The performance of these models was evaluated on the independent test set.
High against low and intermediate ODX scores were predicted by the multivariate model with AUC 0.77 (95% CI 0.56–0.98, p < 0.003). Low against intermediate and high ODX score was predicted with AUC 0.51 (95% CI 0.41–0.61, p = 0.75).
A moderate association between imaging and ODX score was identified. The evaluated models currently do not warrant replacement of ODX with imaging alone.
KeywordsBreast cancer MRI Oncotype DX Imaging features Radiomics Feature selection Logistic regression
- Oncotype DX
Magnetic resonance imaging
Dynamic contrast enhanced magnetic resonance
Receiver operating characteristics
Area under receiver operating characteristics
Compliance with ethical standards
Conflict of interest
Authors have no conflicts of interest to declare.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
The requirement for informed consent was waived by the institutional review board.
- (2006) NSABP study confirms oncotype DX predicts chemotherapy benefit in breast cancer patients. Oncology 20:789–790Google Scholar
- Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel M, André F (2015) Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533–1546CrossRefPubMedPubMedCentralGoogle Scholar
- Delong ER, Delong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845Google Scholar
- Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J (2013) Comparison of PAM50 risk of recurrence score with onco type DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783–2790CrossRefPubMedGoogle Scholar
- Kim JJ, Kim JY, Kang HJ, Shin JK, Kang T, Lee SW, Bae YT (2017) Computer-aided diagnosis-generated kinetic features of breast cancer at preoperative MR imaging: association with disease-free survival of patients with primary operable invasive breast cancer. Radiology 284:45–54CrossRefPubMedGoogle Scholar
- Leijenaar RT, Carvalho S, Velazquez ER, Van Elmpt WJC, Parmar C, Hoekstra OS, Hoekstra CJ, Boellaard R, Dekker ALAJ, Gillies RJ, Aerts HJWL, Lambin P (2013) Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol 52(7):1391–1397CrossRefPubMedGoogle Scholar
- Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, Conzen SD, Whitman GJ, Sutton EJ, Net JM, Ganott M, Huang E, Morris EA, Perou CM, Ji Y, Giger ML (2016a) MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of mammaprint, oncotype DX, and PAM50 gene assays. Radiology 281:382–391CrossRefPubMedPubMedCentralGoogle Scholar
- Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, Fan C, Conzen SD, Zuley M, Net JM, Sutton E, Whitman GJ, Morris E, Perou CM, Ji Y, Giger ML (2016b) Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer 2:16012CrossRefPubMedPubMedCentralGoogle Scholar
- Mazurowski MA, Grimm LJ, Zhang J, Macrom PK, Yoon S, Kim C, Ghate S, Johnson K (2015) Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms. Eur J Radiol 84(11):2117–2122Google Scholar
- Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor–positive breast cancer. Clin Cancer Res:1078–0432Google Scholar
- Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRefPubMedGoogle Scholar
- Wan T, Bloch BN, Plecha D, Thompson CL, Gilmore H, Jaffe C, Harris L, Madabhushi A (2016) A radio-genomics approach for identifying high risk estrogen receptor-positive breast cancers on DCE-MRI: preliminary results in predicting OncotypeDX risk scores. Sci Rep 6:21394. https://doi.org/10.1038/srep21394
- Wu J, Sun X, Wang J, Cui Y, Kato F, Shirato H, Ikeda DM, Li R (2017) Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: model discovery and external validation. J Magn Reson Imaging 46(4):1017–1027Google Scholar